yemenjmedYemen Journal of MedicinecoVolume 4 Issue 1MultidisciplinaryEnglishJanuary- April 2025NNY20250523ArticleTertiary Hospital Experience in Outpatient Treatment of Infantile Hemangiomas: A Prospective StudyEnglishY146152AmnnaRayani1EnglishNNajwa Alkrikshi2EnglishYAbdulhakimAlataweel2EnglishYFatmaAbuzaid2EnglishYAmlHabas3EnglishYElmukhtarHabas4EnglishY10.63475/yjm.v4i1.0033Background: Infantile hemangioma (IH) is observed at varying frequencies among children, impacting 10% of infants. The majority of uncomplicated IH cases experience spontaneous involution, while a minority necessitate intervention. This study aimed to assess the safety and effectiveness of propranolol in treating IH in Libyan pediatric patients. Methods: From 2013 to 2016, a total of 100 patients diagnosed with infantile hemangioma (IH) were monitored at a pediatric tertiary hospital's hematology clinic. Their demographic and clinical information, along with digital images of the lesions, were collected prospectively to evaluate coloration, size, and improvement of the hemangioma lesions. Following parental consent to initiate treatment, a regimen of oral propranolol, atenolol, or a combination of propranolol and steroids was commenced.  Results: The study included 100 children diagnosed with infantile hemangioma (IH), consisting of 62% females and 38% males. Out of these, 68 children were treated exclusively with propranolol, while 12 were started on atenolol. The remaining 20 children received a combination of steroids and propranolol. Hemangioma lesions were primarily located on the face (56%). After an average follow-up duration of 10.53 ±7.21 months, among the 68 children treated solely with propranolol, 12 under the age of 12 achieved complete resolution of their hemangiomas, 15 demonstrated near-complete resolution, and the remaining 41 showed a significant reduction in hemangioma size without considerable disfigurement. Following a six-month discontinuation of propranolol, 2 children from this group experienced a relapse of their lesions. In one instance, the lesion resolved after 12 months of resuming propranolol, while the other required 18 months of treatment. Among the children treated with atenolol, two attained complete resolution, two had near-complete resolution, and 8 exhibited a significant reduction in hemangioma size. No relapses or changes in lesion size were noted after the cessation of atenolol.  Conclusion: Oral propranolol is considered both safe and effective for the treatment of IH at a daily dosage of 2 mg/kg, with no significant adverse effects reported. Atenolol serves as an alternative to propranolol, while steroids, despite their potential side effects, have been shown to improve lesions in certain pediatric patients. Nevertheless, further large multicenter studies are necessary.EnglishPropranolol, Infantile Hemangioma, Angiogenesis, Infantile Hemangioma Therapyhttps://yemenjmed.com/admin/abstract?id=154References1619Land;eacute;autand;eacute;-Labrand;egrave;ze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85-94.Chamli A, Aggarwal P, Jamil RT, Litaiem Nl. Hemangioma. [Updated 2023 Jun 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J. Endothelial progenitor cells in infantile hemangioma. Blood. 2004;103(4):1373-5.Holland KE, Drolet BA. Infantile hemangioma. Pediatr Clin North Am. 2010;57(5):1069-83.Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest. 1994;93(6):2357-64.Carvalho F, Liberal M, Vale F, Rodrigues Santos N, Guedes R. Early Presentation of an Ulcerated Infantile Haemangioma in a Newborn. Cureus. 2022;14(1):e21545.Jacobs AH. Strawberry hemangiomas; the natural history of the untreated lesion. Calif Med. Jan 1957;86(1):8-10.Zheng JW, Wang XK, Qin ZP, Fan X-D, Kai Li5, Yang Y-W, et al. Chinese expert consensus on the use of oral propranolol for treatment of infantile hemangiomas (version 2022). Front Oral Maxillofac Med 2022;4:32-41.You Y, Li Y, Xiao Y, Zhang J. Propranolol vs. steroids in the treatment of infantile hemangiomas: A meta-analysis. Mol Clin Oncol. 2021;15(2):156.Bertrand J, McCuaig C, Dubois J, Hatami A, Ondrejchak S, Powell J. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatric Dermatology. 2011;28(6):649-54.Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol. 2010;163:269and;ndash;74.Restrepo R, Palani R, Cervantes LF, Duarte AM, Amjad I, Altman NR. Hemangiomas revisited: the useful, the unusual and the new. Part 2: endangering hemangiomas and treatment. Pediatr Radiol 2011; 41: 905and;ndash;15.Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610and;ndash;614.Zhang L, Mai HM, Zheng J, Zheng JW, Wang YA, Qin ZP, Li KL. Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. Int J Clin Exp Pathol. 2013;7(1):48-55.Roganovic J. An update on the treatment of high-risk hemangiomas in infants. Eur J Pediatr Surg. 2007;17(2):147.Sharma VK, Fraulin FO, Dumestre DO, Walker L, Harrop AR. Beta-blockers for the treatment of problematic hemangiomas. Can J Plast Surg. 2013;21(1):23-8.Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292-9.Cohen SR, Wang CI. Steroid treatment of hemangioma of the head and neck in children. Ann Otol Rhinol Laryngol. 1972;81:584and;ndash;90.Zheng JW, Wang XK, Qin ZP, Fan XD, Li K, Yang YW, et al. Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas. Shanghai Kou Qiang Yi Xue. 2016;25(3):257-60.Khouri C, Jouve T, Blaise S, Carpentier P, Cracowski JL RM. Peripheral vasoconstriction induced by and;beta;-adrenoceptor blockers: a systematic review and a network meta-analysis. Br J Clin Pharmacol. 2016;82(2):549-60.Kowalska M, Dębek W, Matuszczak E. Infantile Hemangiomas: An Update on Pathogenesis and Treatment. J Clin Med. 2021 Oct 9;10(20):4631.Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64:445and;ndash;451.Tiemann L, Hein S. Infantile Hemangioma: A Review of Current Pharmacotherapy Treatment and Practice Pearls. J Pediatr Pharmacol Ther. 2020;25(7):586-599.Gałązka P, Bereźnicka W, Leis K, Kaczor P, Daniluk-Matraś I, Czajkowski R, et al. Treatment of haemangiomas using propranolol in paediatric patients: a retrospective cohort study. Postepy Dermatol Alergol. 2020;37(4):603-607.Lomenick JP, Reifschneider KL, Lucky AW, Adams D, Azizkhan RG, Woo JG, et al. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009;145:262and;ndash;266.Ballona R, Veland;aacute;squezand;rsquo; F, Kikushima I, Zevallos JP, Nuand;ntilde;ez J, Apagand;uuml;eand;ntilde;o C. Atenolol use for infantile hemangiomas. Indian J Dermatol Venereol Leprol. 2021;87(2):321.Apfelberg DB, Maser MR, White DN, Lash H. A preliminary study of the combined effect of neodymium: YAG laser photocoagulation and direct steroid instillation in the treatment of capillary/cavernous hemangiomas of infancy. Ann Plast Surg. 1989;22(2):94-104.Schulz AS, Urban J, Gessler P, Behnisch W, Kohne E, Heymer B. Anaemia, thrombocytopenia and coagulopathy due to occult diffuse infantile haemangiomatosis of spleen and pancreas. Eur J Pediatr. 1999;158(5):379-83.